Back to Search
ALEX ADJEI, MD PHD
MD PHD
Medical Oncology Physician
NPI: 1982680583IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
245715(NY)38085(MN)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1982
Research & Publications (20)
Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects.
PMID 18232020·Birth Defects Res A Clin Mol Teratol·2008
8-other
Novel combinations based on epidermal growth factor receptor inhibition.
PMID 16857826·Clin Cancer Res·2006
6-review
Sequencing bortezomib with chemotherapy and targeted agents.
PMID 16250928·Clin Lung Cancer·2005
6-review
Targeting multiple signal transduction pathways in lung cancer.
PMID 16159418·Clin Lung Cancer·2005
6-review
The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.
PMID 16354319·Clin Lung Cancer·2005
6-review
Intracellular signal transduction pathway proteins as targets for cancer therapy.
PMID 15983388·J Clin Oncol·2005
6-review
Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent.
PMID 15217974·Clin Cancer Res·2004
6-review
Current data with pemetrexed (Alimta) in non-small-cell lung cancer.
PMID 14720339·Clin Lung Cancer·2003
8-other
Human estrogen sulfotransferase (SULT1E1) pharmacogenomics: gene resequencing and functional genomics.
PMID 12922923·Br J Pharmacol·2003
7-preclinical
Immunohistochemical assays of farnesyltransferase inhibition in patient samples.
PMID 12710205·Methods Mol Med·2003
6-review
Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer.
PMID 12721252·J Clin Oncol·2003
3-trial
Pemetrexed (Alimta): a novel multitargeted antifolate agent.
PMID 12722874·Expert Rev Anticancer Ther·2003
6-review
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
PMID 12855626·Clin Cancer Res·2003
3-trial
An overview of farnesyltransferase inhibitors and their role in lung cancer therapy.
PMID 12867063·Lung Cancer·2003
6-review
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
PMID 12538459·Clin Cancer Res·2003
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- ELM AND CARLTON ST
BUFFALO, NY 14263 - Phone
- (716) 845-2300
Quick Facts
- NPI
- 1982680583
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 44
- Publications
- 20
Are you this provider?
Claim Your Profile